The research project TOBI focuses on the identification of molecules that can be used as targets for new drugs against obesity-related disorders such as diabetes.
Seven academic research institutions together with 3 small and medium-size enterprises (SMEs) combine their expertise and efforts for reaching this aim.
The project is coordinated by Prof. Thomas Stulnig at the Medical University of Vienna, Austria, and is endowed with EUR 2.98 million of EU funding.
TOBI pays particular attention to the adipokines.
The TOBI-consortium is formed by 10 partners from 5 different countries, including 3 SMEs and 7 universities. This consortium combines scientific and technical expertise of following partners: Medical University of Vienna (AT), biolution GmbH (AT), University of Cologne (DE), University of Ancona (IT), Genfit SA (FR), pharm-analyt GmbH (AT), University of Durham (UK), Institute Pasteur de Lille (FR), University of Edinburgh (UK) and the University of Graz (AT). more information
For optimizing their collaboration, the TOBI-partners established a TOBI Toolbox. This TOBI Toolbox consists of the TOBI Standards and the TOBI Biobank. TOBI Standards are standard operating procedures (SOPs) – detailed written working instructions - that guarantee uniform operating methods in clinical trials, animal and in vitro experiments of all consortium partners. The TOBI Biobank is a collection of human samples including standardised characterisation of donors that is made available to all TOBI-partners.